$174 Billion is the total value of Versant Venture Management, LLC's 7 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 40.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GKOS | New | Glaukos Corporation | $76,010,229,000 | – | 3,142,217 | +100.0% | 43.59% | – |
| CLVS | Clovis Oncology, Inc. | $37,465,975,000 | +4.6% | 407,416 | 0.0% | 21.49% | -52.7% | |
| OCUL | New | Ocular Therapeutix, Inc. | $31,148,299,000 | – | 2,215,384 | +100.0% | 17.86% | – |
| FPRX | Five Prime Therapeutics, Inc. | $16,808,219,000 | -38.0% | 1,092,152 | 0.0% | 9.64% | -72.0% | |
| AKAOQ | Achaogen, Inc. | $7,379,435,000 | -4.5% | 1,281,152 | 0.0% | 4.23% | -56.8% | |
| BITI | Biotie Therapies Corp.ads | $3,516,916,000 | -34.5% | 268,672 | 0.0% | 2.02% | -70.4% | |
| CBAY | CymaBay Therapeutics, Inc. | $2,034,285,000 | -27.9% | 1,048,601 | 0.0% | 1.17% | -67.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-10-28
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-03 |
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.